Immix Biopharma — Positive newsflow continues for NEXICART-2
Immix Biopharma has announced a positive clinical update for the US-based Phase I/II NEXICART-2 trial, investigating lead CAR-T candidate NXC-201...
283 Views
Immix Biopharma — Steady progress in Q125
Immix Biopharma’s Q125 results reflect steady progress for NXC-201, its lead CAR-T candidate in clinical development to address amyloid light chain...
280 Views
Immix Biopharma — All eyes on NEXICART-2
Immix’s FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis....
361 Views
Immix Biopharma — All eyes on NEXICART-2
Immix’s FY24 results summarize a period of focus on its lead CAR-T asset, NXC-201, which is being developed for amyloid light chain amyloidosis....
301 Views
Immix Biopharma — NXC-201 receives FDA RMAT designation
Immix Biopharma has been granted a Regenerative Medicine Advanced Therapy (RMAT) designation by the US Food and Drug Administration (FDA) for the...
220 Views